This Phase II trial is evaluating how safe and tolerable a targeted therapy (entrectinib) is in people with newly diagnosed non-squamous non-small cell lung cancer an advanced solid cancers with NTRK fusions or ROS1 gene rearrangements.
This trial is treating patients with non-squamous non-small cell lung cancer and advanced solid cancers.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have been diagnosed with cancer, but have not received any treatment.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A single-arm, open-label, phase II trial of the tumour response to entrectinib in patients with advanced tumours harbouring NTRK fusions or ROS1 gene rearrangements detected by comprehensive genomic profiling
Other Non-Commercial Sponsor
University of Sydney
All participants in this trial will be treated with Entrectinib. Entrectinib will be administered orally at a dose of 600mg once daily from days 1-28 on a 28-day cycle until disease progression, intolerable toxicity or withdrawal.
Recruiting Hospitals Read More